CONSOLIDATED STATEMENT OF CASH FLOWS(USD ($)) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012		Sep. 30, 2011
Cash flows from operating activities:
Net income	$ 186,016		$ 242,472
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization	56,332		56,245
Deferred income taxes	(13,830)		25,672
Gain on disposal of assets	(2,243)		(2,365)
Stock-based compensation	15,363		16,667
Pension settlement/curtailment	874		3,583
Spanish tax charge	72,362
Payments pursuant to Spanish tax settlement	(105,503)
Changes in assets and liabilities:
Trade receivables	(66,364)		(71,928)
Inventories	(3,751)		(6,949)
Accounts payable	(33,652)		(18,987)
Accruals for incentive compensation	14,927		(48,519)
Other current payables and accrued expenses	29,095		(57,524)
Other assets	(20,087)		(35,352)
Other liabilities	13,366		13,711
Net cash provided by operating activities	142,905		116,726
Cash flows from investing activities:
Additions to property, plant and equipment	(84,176)		(74,743)
Purchase of insurance contracts	(1,127)		(1,733)
Maturity of net investment hedges	1,960		(2,220)
Proceeds from disposal of assets	223		469
Net cash used in investing activities	(83,120)		(78,227)
Cash flows from financing activities:
Cash dividends paid to shareholders	(75,458)		(65,174)
Net change in revolving credit facility borrowings and overdrafts	8,376		83,292
Repayments of long-term debt			(100,000)
Proceeds from issuance of stock under stock-based compensation plans	7,664		14,319
Excess tax benefits on stock-based payments	6,920		5,223
Net cash used in financing activities	(52,498)		(62,340)
Effect of exchange rate changes on cash and cash equivalents	1,615		(208)
Net change in cash and cash equivalents	8,902		(24,049)
Cash and cash equivalents at beginning of year	88,279		131,332
Cash and cash equivalents at end of period	97,181		107,283
Interest paid	46,689		53,475
Income taxes paid	$ 163,767	[1]	$ 60,171

[1] The 2012 amount includes $105.5 million pursuant to the Spanish tax settlement (see Note 6).